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The fibroblast growth factor receptor 4 (FGFR4)-
R388 single-nucleotide polymorphism has been
associated with cancer risk and prognosis. Here we
show that the FGFR4-R388 allele yields a receptor
variant that preferentially promotes STAT3/5
signaling. This STAT activation transcriptionally
induces Grb14 in pancreatic endocrine cells to pro-
mote insulin secretion. Knockin mice with the
FGFR4 variant allele develop pancreatic islets that
secrete more insulin, a feature that is reversed
through Grb14 deletion and enhanced with FGF19
administration. We also show in humans that the
FGFR4-R388 allele enhances islet function and may
protect against type 2 diabetes. These data support
a common genetic link underlying cancer and hyper-
insulinemia.
INTRODUCTION
Type 2 diabetes is an increasingly prevalent metabolic disorder
characterized by hyperinsulinemia. This disease is associated
with many complications, including a well-established increased
risk of cancer (Rose et al., 2007). A prototypic example is the
association between breast cancer and diabetes as noted in
several epidemiologic studies (Lawlor et al., 2004; Lann and
LeRoith, 2008). Nevertheless, the mechanisms underlying this
association remain controversial. In particular, the role of insulin
underpinning this cancer-diabetes connection is unclear
(LeRoith, 2010). The contribution from insulin, rather than dia-
betes per se, is supported by epidemiologic studies (Lann and
LeRoith, 2008) and by the mitogenic actions of insulin-like
growth factors on breast tissue (Ferguson et al., 2012). Further-
more, the insulin receptor (IR) is frequently overexpressed inCbreast cancer cells (Belfiore et al., 1996; Lawlor et al., 2004;
Larsson et al., 2007). Elevated insulin concentrations may also
stimulate tumor growth by increasing bioavailable insulin-like
growth factor (IGF-1) (Larsson et al., 2007), which in turn has
been shown to predict premenopausal breast cancer risk. Insu-
lin also inhibits the production of sex-hormone-binding globulin,
leading to increased bioavailable sex steroids (Larsson et al.,
2007; Kahn et al., 2002).
In this work we report a genetic link between cancer and
hyperinsulinemia through a pancreatic islet pathway. We exam-
ined a single-nucleotide polymorphism (SNP) in the fourth mem-
ber of the fibroblast growth factor receptor family, FGFR4,
which has been implicated in cancer risk and progression. In
particular, the common R388 allele of this receptor (FGFR4-
R388) has been associated with breast cancer progression
and treatment resistance (Bange et al., 2002; Thussbas et al.,
2006). Meta-analyses have supported an increased risk of
cancers associated with this polymorphism (Xu et al., 2011;
Xu et al., 2010). This SNP replaces a neutral glycine (G388)
with a charged arginine (R388) in the transmembrane domain,
a general hot spot in receptor tyrosine kinases for disease-
related sequence variations; however, its mechanism of action
remains unclear. Here we show that this cancer-associated
FGFR4 variant signals in a tissue-specific manner to enhance
pancreatic insulin secretion.RESULTS
The Cancer-Associated FGFR4-R388 Allele Promotes
Pancreatic Insulin Secretion
While multiple FGFRs, including FGFR4, are expressed in adult
pancreatic islets (Oberg-Welsh and Welsh, 1996; Hughes,
1997; Le Bras et al., 1998; Dichmann et al., 2003; Takaishi
et al., 2000), their actions in modulating beta islet cell signaling
and physiologic functions remain unclear. To specifically
examine functional differences between prototypic FGFR4
(FGFR4-G388) and the cancer-associated FGFR4-R388 variant,ell Metabolism 17, 929–940, June 4, 2013 ª2013 Elsevier Inc. 929
Figure 1. FGFR4-G388 and FGFR4-R388
Promote Distinct Signals in Pancreatic Islet
Cells
(A) Pancreatic islet RIN cells expressing prototypic
FGFR4-G388 (left) or the polymorphic variant
FGFR4-R388 (right) were treated under serum-free
conditions with the non-FGFR-selective ligand
FGF1, the FGFR2-selective ligand FGF7, or the
FGFR4-selective ligand FGF19. Responses were
monitored with antibodies to phosphorylated
FGFR (pFGFR), the immediate FGFR substrate
(pFRS2), phospholipase-C g (pPLC-g), or pErk1/2
(MAPK) as indicated. Other than PLC-g which
weakly associates with FGFR4 (Vainikka et al.,
1994), cells expressing FGFR4-G388 exhibit intact
responses. In contrast, FGFR4-R388 cells fail to
show measureable FRS2 activation.
(B) FGFR4-R388-expressing cells secrete signifi-
cantly (p < 0.01) more insulin than FGFR4-G388
cells in the presence of glucose (left panel).
(C) Electron microscopic examination reveals that
RIN cells with empty vector (pcDNA) or FGFR4-
G388 have well-developed rough endoplasmic
reticulum (*), large Golgi complexes (G), and
numerous secretory granules (arrows). In contrast,
and consistent with the increase in insulin secre-
tion but reduced storage induced by FGFR4-R388,
cells expressing this FGFR4 variant have very few
stored granules.
See also Figure S1.
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cells that endogenously express FGFR4 and its coreceptor,
klotho beta (KLB). Cells were stimulated with FGF1, which stim-
ulates all FGFR isotypes, the FGFR2-selective ligand FGF7, or
the FGFR4-selective ligand FGF19. FGFR responses confirmed
the anticipated activation of the immediate FGFR substrate 2
(FRS2) and pErk1/2 MAPK in wild-type RINm5F cells (Figure S1A
available online). Cells expressing FGFR4-G388 similarly ex-
hibited the predicted FGFR signaling responses (Figure 1A). In
contrast, FGFR4-R388-expressing cells failed to activate FRS2
in response to FGF stimulation. Nevertheless, FGFR4-R388-
expressing islet cells secreted nearly twice as much insulin as
cells expressing the wild-type (FGFR4-G388) receptor (p <
0.01) (Figure 1B). These functional changes were reflected in
ultrastructural parameters of secretory activity; electron micro-
scopy revealed that islet cells expressing FGFR4-G388 had
well-developed rough endoplasmic reticulum, large Golgi com-
plexes, and numerous secretory granules (Figure 1C), whereas
islet cells expressing FGFR4-R388 had evidence of active syn-930 Cell Metabolism 17, 929–940, June 4, 2013 ª2013 Elsevier Inc.thesis but very few stored secretory
granules, consistent with increased
secretion (Figure 1C). The increased insu-
lin secretion by FGFR4-R388 cells was
sensitive to diazoxide inhibition but not
to enhancement by tolbutamide treat-
ment (Figure S1B). Additionally, expres-
sion of glucose-sensing genes including
hexokinase 1 (HK1) and K+ATP channel
subunits, KCNJ11, KCNJ15, and ABCC8were not measurably influenced by the two FGFR4 isoforms
(data not shown).
Gene Profiling Identifies Grb14 Induction
by FGFR4-R388
To identify genes involved in the divergent signaling and actions
displayed by the FGFR4 isoforms, we performed microarray
gene expression profiling comparing pancreatic insulin-produc-
ing cells expressing empty vector, FGFR4-G388, or FGFR4-
R388. We sought to identify a target that can potentially
attenuate wild-type FGFR signaling by FGFR4-R388 (Table
S1). This candidate proved to be the adaptor protein Grb14
(accession number NM_03162) as determined by quantitative
real-time PCR andwestern blotting. Figure 2 depicts representa-
tive findings from these studies, confirming that islet cells
expressing FGFR4-R388 have increased levels of insulin
messenger RNA (mRNA) (Figure 2B) accompanied by a nearly
4-fold and 10-fold induction in Grb14 mRNA (Figures 2A and
2B) and protein (Figure 2C) compared with cells expressing
Figure 2. The Grb14 Adaptor Protein Is a
Target of FGFR4-R388
(A) RT-PCR examination of RNA from pancreatic
RINm5F cells reveals upregulation of the adaptor
protein Grb14 in cells expressing FGFR4-R388. In
contrast, Grb7 and total IR are unchanged.
(B) Real-time PCR confirms significant (p < 0.01)
induction of Grb14 and insulin mRNA expression
by FGFR4-R388 cells.
(C) Cells expressing FGFR4-G388, FGFR4-R388,
or empty vector (pcDNA) were examined without
and with glucose in each lane respectively. Grb14
is induced by FGFR4-R388 even when expressed
at lower levels than FGFR4-G388.
(D) Downregulation of Grb14 in FGFR4-R388
cells restores FRS2a responsiveness to FGF
stimulation.
See also Table S1.
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signaling in these cells was demonstrated by small interfering
RNA (siRNA) downregulation of the adaptor which restored
FRS2a responsiveness to FGF stimulation in FGFR4-R388 RIN
cells (Figure 2D). Of note, Grb7 and Grb10, the two other related
members of the Grb7/10/14 family, were not altered by FGFR4-
G388 or its cancer-associated variant, FGFR4-R388 (Figure 2A
and data not shown).
STAT3/5 Activation by the Cancer FGFR4-R388 Allele
Induces Pancreatic Grb14 Transcription
To determine mediators responsible for Grb14 induction by
FGFR4-R388, we examined the impact of candidate FGFR
signaling effectors. FGFR mutations associated with thanato-
phoric dysplasia result in constitutive STAT activation (Hart
et al., 2000b). This prompted us to compare the ability of the
two FGFR4 isoforms to activate STAT signaling. Figure 3A dem-
onstrates the sustained impact of FGFR4-R388 compared with
FGFR4-G388 on STAT3 and STAT5 phosphorylation. To
examine the involvement of STAT activation in Grb14 induction,
we knocked down STAT3 or STAT5 in FGFR4-R388 cells (Fig-
ure 3B). This reduction of STAT3 or STAT5 was associated
with diminished Grb14 protein (Figure 3B) and mRNA levels (Fig-
ure 3C). Furthermore, chromatin immunoprecipitation (ChIP)
demonstrated enhanced pSTAT3 and pSTAT5 binding to two
regions (504/495; 21/12) harboring STAT binding sites in
the 50 Grb14 promoter (Figure 3D) in FGFR4-R388 compared
to FGFR4-G388 cells (Figure 3E). Conversely, knockdown of
Grb14 resulted in STAT3 upregulation (Figure S2A), suggesting
an interregulatory feedback loop between STAT3 and Grb14Cell Metabolism 17, 929–regulation. Moreover, forced expression
of STAT3 or STAT5 in MIN6 cells resulted
in enhanced glucose-stimulated insulin
secretion (Figure S2B).
FGFR4-R388-Mediated Grb14
Induction Alters Insulin Receptor
Signaling
Given the ability of FGFR4-R388 to
induce Grb14, we next examined theimpact of this adaptor protein in mediating FGFR4 isoform
signaling in pancreatic insulin-producing cells. Grb14 is recog-
nized for its ability to potently bind the autophosphorylated IR
and inhibit its activity on other substrates (Holt and Siddle,
2005). Thus, we examined the ability of FGFR4-R388 to inter-
rupt IR signaling in pancreatic insulin-producing cells. RIN cells
expressing FGFR4-R388 demonstrated increased IR phosphor-
ylation compared with FGFR4-G388-expressing cells (Fig-
ure 4A). To better define the impact of FGFR4-R388, we used
antibodies directed at specific IR phosphorylation sites (Fig-
ure 4B). FGFR4-R388 cells displayed increased phosphoryla-
tion of IR-Y1158/1162 within the kinase pocket compared
with FGFR4-G388 cells. In contrast, the IR juxtamembrane
Y972 site showed reduced phosphorylation in FGFR4-R388
cells. Consistent with the diminished IR-Y972 phosphorylation
at the IRS1-docking site, total IRS1 levels were reduced in
FGFR4-R388 cells compared to FGFR4-G388 cells (Figure 4B).
Further, the reduction in IRS1 was associated with diminished
pY-IRS1 in FGFR4-R388 versus FGFR4-G388 cells (Figure 4B).
Proteasomal inhibition with LLNL restored IRS1 levels in
FGFR4-R388-expressing cells (Figure 4B, right), consistent
with increased degradation as an underlying mechanism for
reduced levels of this IR substrate in these cells. These site-
specific reciprocal changes imposed by FGFR4-R388 are
consistent with protection against dephosphorylation by
PTP1b at IR-1158/1162 and result in enhanced dephosphoryla-
tion at IR-Y972 (Nouaille et al., 2006). Consistent with this
model, pervandate abrogated the differential effects of
FGFR4-R388 on IR-Y972 to restore IRS1 and reduce IRS2
levels (Figure 4B, right).940, June 4, 2013 ª2013 Elsevier Inc. 931
Figure 3. FGFR4-R388 Preferentially Sig-
nals through STAT3/5 to Induce Grb14
(A) Pancreatic islet RINm5F cells expressing
FGFR4-G388 or FGFR4-R388 were compared for
their ability to signal through STAT3 or STAT5
during a time-course reflecting the duration of
exposure to 8 mmol/liter glucose. Note pY-STAT3
and pY-STAT5 responses by FGFR4-R388 cells,
which are appreciably greater and more sustained
than in FGFR4-G388 cells.
(B) FGFR4-R388 cells were transfected with siRNA
oligonucleotides to knock down STAT3 or STAT5
as indicated. Western blotting demonstrates
STAT3 or STAT5 reduction and associated
diminished Grb14 expression. For each knock-
down, three independent siRNA oligonucleotides
were used yielding similar results (data not shown).
(C) Quantitative real-time PCR of STAT3/5 down-
regulated cells from panel b show corresponding
reduction in Grb14 mRNA expression.
(D) The 50 Grb14 region contains two putative
STAT binding sites as indicated. The highlighted
regions were targeted for chromatin immunopre-
cipitation (ChIP) examination.
(E) ChIP assays show enhanced pY-STAT3 and
pY-STAT5 binding to the Grb14 promoter in cells
expressing FGFR4-R388 compared to FGFR4-
G388. Densitometric values from three indepen-
dent experiments are shown immediately below.
See also Figure S2 and Table S4.
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Enhance Pancreatic Islet Function
To determine whether the induction of Grb14 by FGFR4-R388 is
involved in mediating the effects on increased insulin secretion,
we used siRNA to target this adaptor protein. Figure 4C reveals
effective Grb14 knockdown in FGFR4-R388-expressing RIN
islet cells (upper panel) and demonstrates the corresponding
impact on insulin secretion (lower panel). FGFR4-R388 cells
showed reduced insulin secretion in response to Grb14 knock-
down, consistent with Grb14 involvement in mediating
enhanced insulin secretion by FGFR4-R388 RIN cells.
Conversely, forced Grb14 expression in mouse MIN6 islet cells
promoted glucose-stimulated insulin secretion (Figure S2B).932 Cell Metabolism 17, 929–940, June 4, 2013 ª2013 Elsevier Inc.To determine whether the IR represents
a target of Grb14 in mediating insulin
secretion, we downregulated the IR (Fig-
ure 4D). IR knockdown in FGFR4-G388
cells recapitulated the effect of FGFR4-
R388 on insulin secretion (Figure 4D),
consistent with an IR autofeedback
effect.
Pancreatic Islet Morphology in
FGFR4-R385 Knockin Mice
To determine the impact of FGFR4-R388
on pancreatic islet function in a physio-
logic system, we examined mice with
knockin (KI) of the mouse homolog,
FGFR4-R385, at different ages. Impor-
tantly, this mouse model does not alterFGFR4 expression levels in the pancreatic islets (Figure 5A) or
other tissues (Seitzer et al., 2010) in which this receptor is nor-
mally expressed including liver and muscle. Systematic exami-
nation of the pancreas of FGFR4-R385 KI mice identified
normal pancreatic exocrine elements including ducts and acini,
and endocrine islets scattered with the usual distribution (Fig-
ure 5). Immunohistochemical stains to localize insulin showed
a reduction in insulin-containing B cells in mice harboring the
FGFR4-R385 allele (Figure 5B). In contrast, there was a relative
increase in the population of glucagon-expressing A cells
(Figure 5C).
To determine whether the signaling differences identified in
pancreatic islet cells are evident in vivo, we examined Grb14
Figure 4. FGFR4-R388-Mediated Grb14 In-
duction Impairs Insulin Receptor Signaling
(A) Pancreatic RINm5F cells expressing empty
vector (pcDNA), FGFR4-G388, or FGFR4-R388
were serum-deprived overnight (–) then exposed
to glucose for 15 min (+). Total cell lysates were
immunoprecipitated (IP) with an antibody to
insulin receptor (IR) and blotted with an antibody
to phospho-tyrosine (pY20) or to IR as
indicated. FGFR4-R388 cells show increased IR
phosphorylation.
(B) Experiments were performed as in (A) with
site-specific anti-phospho-IR antibodies. FGFR4-
R388 cells show increased pY-IR 1158/1162
within the kinase pocket. In contrast, the IR
juxtamembrane Y972 site shows diminished
phosphorylation in response to glucose stimula-
tion. Consistent with the diminished IR-Y972
phosphorylation at the IRS1 docking site, IRS1
levels are lower in FGFR4-R388 cells compared to
FGFR4-G388 cells. Levels of IRS1 tyrosyl phos-
phorylation in response to glucose are also
impaired in FGFR4-R388 cells. These cells were
also examined in the absence (–) or presence (+) of
the proteasomal inhibitor LLnL, which restores
IRS1 levels in FGFR4-R388 cells (right upper
panel) and pervandate (right lower panel). The
reciprocal effect of FGFR4-R388 on site-specific
IR phosphorylation and diminished IRS1 is again
noted. Pervanadate restores IRS1 in FGFR4-R388
cells to levels resembling those of FGFR4-G388
cells. Data shown are representative of three
independent experiments.
(C) So that the impact of Grb14 on insulin secretion
could be determined, FGFR4-R388 cells were
transfected with siRNA targeting this adaptor
protein. The upper panel confirms effective
Grb14 knockdown in siRNA-transfected cells (+)
compared to scrambled-sequence controls (–).
The lower panel depicts the impact on insulin
secretion in corresponding conditioned media.
Cells downregulated for Grb14 show reduced
insulin secretion. Two additional siRNA oligonu-
cleotides yielded similar results (data not shown).
(D) Impact of insulin receptor downregulation on
insulin secretion in FGFR4-tranfected cells. Cells
expressingFGFR4-G388,FGFR4-R388, or their empty vector pcDNAwere transfectedwith siRNA targeting the IR. Theupper panel demonstrates theeffectiveness
of the siRNA (+) versus scrambled-sequence controls (–) in downregulating the IR in each of the FGFR isotypes. The lower panel demonstrates the rise in insulin
secretion in response to IR downregulation. Values reflect the mean + SEM obtained in two independent experiments each performed in triplicate treatments.
See also Table S5.
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expression in glucagon-containing A cells, but the intensity of
Grb14 staining was increased in B cells of FGFR4-R385 KI
mice compared with wild-type controls (Figure 5D). A similar
increase in Grb14 staining in B cells was also noted in
primary human islets harboring the FGFR4-R388 variant (Fig-
ure S3A). Reminiscent of the in vitro effects of FGFR4-R388,
the B cells of the pancreatic islets of FGFR4-R385 KI
mice showed diminished pFRS2 (Figure 5E) and reduced
IRS1 expression (Figure 5F) compared to those of FGFR4-
G385 littermates. Moreover, expression of HK1, KCNJ11,
and KCNJ15 was not significantly altered across FGFR4
genotypes (data not shown). Additionally, Grb14 levels were
not altered in other surveyed tissues including liver andCskeletal muscle tissue across FGFR4 genotypes (data not
shown).
To quantify pancreatic islets across FGFR4genotypes,weper-
formed detailed histomorphometric analyses on 6-month-old
mice. These analyses confirmed that the endocrine islet area as
a proportion of overall pancreatic area was not increased and
indeed was modestly reduced from 0.0090 ± 0.0023 in FGFR4-
G385mice (n = 8) to 0.0062 ± 0.0027 in FGFR4-R385+/ (n = 10)
and0.0062±0.0018 inFGFR4-R385+/+ (n = 10)mice (FigureS3B).
Moreover, pancreatic islet number was not significantly different
across FGFR4 genotypes (data not shown). Additionally,
measures of apoptosis and proliferation showed no significant
differences between islets derived from mice of different FGFR4
genotypes on regular (Figure S3C) or high-fat diet (Figure S3D).ell Metabolism 17, 929–940, June 4, 2013 ª2013 Elsevier Inc. 933
Figure 5. Pancreatic Islet Morphology in FGFR4-R385 Knockin mice
To determine the in vivo impact of FGFR4 isoforms on pancreatic endocrine
morphology, we examined pancreatic tissues of mice with knockin of the
FGFR4-R385 allele compared with FGFR4-G385 littermate controls. FGFR4
staining demonstrates comparable expression of the receptor across
genotypes (A). The islets of mice carrying an FGFR4-R385 allele were of
comparable size but exhibited reduced insulin content (B), whereas glucagon-
positive cells were not reduced (C). Grb14 shows preferential expression in
glucagon-containing A cells, but the intensity of Grb14 staining was increased
in B cells of FGFR4-R385+/ and FGFR4-R385+/+ KI mice compared with their
littermate controls (D). Impaired FGFR signaling in the endocrine pancreas is
supported by diminished pFRS2 (E) and attenuated IR signaling evidenced by
reduced IRS1 (F). See also Figure S3.
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Insulin Secretion In Vivo
To determine the impact of the FGFR4-R385 allele on insulin
secretion in vivo, we performed glucose tolerance testing on
mice with knockin of this allele. Initial examinations were per-
formed on mice fed regular diet and exhibiting no significant
differences in body weight across FGFR4 genotypes. Moreover,
indirect calorimetric measurements demonstrated no measure-
able differences in oxygen consumption, carbon dioxide produc-
tion, respiratory quotients, or heat production across FGFR4
genotypes (Figure S4A). Nevertheless, FGFR4-R385+/ and
FGFR4-R385+/+ mice showed modest improvement of glucose
tolerance even when maintained on regular diet compared with934 Cell Metabolism 17, 929–940, June 4, 2013 ª2013 Elsevier Inc.their FGFR4-G385 littermates (Figures 6A and 6B). These
FGFR4-R385 KI mice also showed enhanced insulin secretion
(Figures 6C and 6D), a feature noted as early as 6 weeks of
age (data not shown). Additionally, insulin administration showed
no signs of systemic (Figure S4B) or tissue insulin resistance
(Figure S4C), further excluding peripheral resistance as a cause
of the hyperinsulinemia. Circulating glucagon levels were
reduced in FGFR4-R385 KI mice compared to FGFR4-G385
littermates (Figure S4D).
We next examined animals maintained on a high-fat diet
(HFD). Figure 6E demonstrates that compared to FGFR4-G385
animals, FGFR4-R385 KI mice can better tolerate HFD-induced
hyperglycemia. Moreover, administration of the FGFR4 ligand
FGF19 resulted in further improvement in glucose tolerance (Fig-
ures 6F and 6G) accompanied by significantly enhanced insulin
secretion (Figure 6H).
The Grb14 Adaptor Mediates Pancreatic
Hyperinsulinemia in FGFR4-R385 Knockin Mice
Having demonstrated an in vitro role for Grb14 in mediating
FGFR4-R388 action and for the FGFR4 variant in mediating
enhanced insulin secretion in vivo, we focused on the extent to
which the Grb14 adaptor contributes to islet insulin secretion
in vivo. To this end, we generated double-mutant FGFR4-
R385+//Grb14/ mice. These studies confirmed that loss of
Grb14 reverses the enhanced insulin secretion by FGFR4-
R385 KI mice (Figures 7A and 7B).
To further delineate the functional role of Grb14 in mediating
pancreatic insulin secretion by the FGFR4 variant allele, we iso-
lated primary islets for assessment of insulin secretion ex vivo.
These studies demonstrated enhanced insulin secretion by
primary islets from FGFR4-R385+/ KI mice compared with
those from FGFR4-G385 littermates (Figure 7C). Importantly,
loss of Grb14 reversed the impact of FGFR4-R385 on insulin
secretion: FGFR4-R385+//Grb14/ islets secrete less insulin
than those from FGFR4-R385+/ animals. Taken together, these
findings provide strong evidence for Grb14 involvement in
modulating FGFR4-R385 pancreatic insulin secretion.
The FGFR4-R388 Allele and Glycemic Traits in Humans
To examine the functional consequences of our experimental
findings and the metabolic effects of the FGFR4-R388 poly-
morphic allele in humans, we examined the relationship between
this variant, quantitative glycemic traits related to insulin secre-
tion, and type 2 diabetes in different populations. In a cross-
sectional examination of 1990 German nondiabetic participants
(Kantartzis et al., 2011), the FGFR4-R388 allele was associated
with lower fasting glycemia in 1,310 women (p = 0.054 in the
additive model, p = 0.27 in the dominant model) but not in the
680 males (p = 0.92 in the additive mode, p = 0.74 in the domi-
nant model). In agreement with these cross-sectional data
from the German study, in the Finnish cross-sectional metabolic
syndrome in men (METSIM) study (Stanca´kova´ et al., 2009), the
FGFR4-R388 allele was not associated with age, body mass in-
dex (BMI), the insulinogenic index, HOMA-B, or glucose toler-
ance (all p > 0.05; Table S2).
To ensure that sample size and ethnicity were not limiting in
detecting potential associations, we mined available genome-
wide meta-analysis data sets generated by the Meta-analysis
Cell Metabolism
Cancer-Associated FGFR4 and Islet Hyperinsulinemiaof Glucose and Insulin-Related Traits Consortium (MAGIC),
accessed at http://www.magicinvestigators.org. The FGFR4-
R388 allele was associated with lower fasting glucose (p =
0.03) in 12,713 individuals and lower insulin resistance by
homeostasis model assessment (HOMA-IR) (Matthews et al.,
1985) in 11,163 individuals (p = 0.0004). Additionally, the
FGFR4-R388 allele was nominally associated with higher fasting
proinsulin levels, adjusted for concomitant fasting insulin (p =
0.01) providing supportive evidence for the cancer-associated
FGFR4 variant in human insulin secretion.
Finally, we turned to the Diabetes Prevention Program (DPP), a
multiethnic clinical trial conducted in the United States in which
an intensive lifestyle intervention or metformin were compared
with placebo for diabetes prevention (Knowler et al., 2002). In
this cohort of 3,453 overweight participants with elevated fasting
glucose and impaired glucose tolerance, there were no associa-
tions of genotype at FGFR4-R388with baseline insulinogenic in-
dex or HOMA-IR, nor were there significant interactions between
genotype and intervention on 1-year outcomes for these traits.
However, the FGFR4-R388 allele was associated with a greater
decrease in HOMA-IR at 1 year (p = 0.009); analyses stratified by
treatment group showed a significant decrease in the metformin
arm only (p = 0.001), though there was no significant interaction.
There was an association of the FGFR4-R388 allele with lower
diabetes incidence in the overall cohort (hazard ratio per allele,
0.87 [95% confidence interval, 0.76–1.00], p = 0.048), after
adjustment for treatment group, sex, age at randomization,
and self-reported ethnicity. Sex-specific analyses revealed that
most of the diabetes preventive effect in the DPP occurred in
men treated with metformin (Table S3; p for SNP 3 treatment
interaction = 0.03). This was correlated with a significant reduc-
tion in HOMA-IR in this subgroup at 1 year (p < 0.001).
DISCUSSION
The current study demonstrates that the same FGFR4-R388
polymorphic allele recognized for its cancer actions in mouse
(Seitzer et al., 2010) and in man (Xu et al., 2011; Xu et al.,
2010; Bange et al., 2002; Thussbas et al., 2006; Wang et al.,
2004; Morimoto et al., 2003; Streit et al., 2004) also modulates
insulin production. Compared with FGFR4-G388, the FGFR4-
R388 variant enhances islet insulin production. Importantly,
these receptor isoforms have divergent signaling properties in
different tissues as demonstrated in breast (Stadler et al.,
2006) and pituitary cells (Tateno et al., 2011). In pancreatic
insulin-producing cells, the FGFR4 variant signals in a distinct
manner to promote insulin secretion.
Our study identifies the Grb14 adaptor protein as a critical
mediator linking the cancer-associated FGFR4 variant with
insulin production. Grb14 induction by FGFR4-R388 was identi-
fied in the endocrine pancreas but not in peripheral tissues,
including liver and skeletal muscle. Forced downregulation of
Grb14 in islet cells expressing FGFR4-R388 resulted in restora-
tion of FGFR and IR signaling. Given the interruptive functions of
Grb14 on IR in peripheral tissues (Depetris et al., 2005; Cooney
et al., 2004), we examined whether the IR in pancreatic insulin-
producing cells is similarly targeted by Grb14-induced antago-
nism. Indeed, Grb14 induction by FGFR4-R388 resulted in
site-selective defects in IR phosphorylation in islet cells. ThisCwas supported by the ability of FGFR4-R388-induced Grb14 to
protect the IR kinase loop (Y1158) from dephosphorylation.
This effect was associated with enhanced dephosphorylation
of IR-Y972, thus diminishing IRS-1 recruitment. These findings
are consistent with earlier data demonstrating effective Grb14
displacement of PTP1b away from the IR kinase (Nouaille
et al., 2006). That the pancreatic IR is a functional target of
FGFR4-R388-mediated Grb14 induction was suggested from
downregulation of the IR in cells expressing FGFR4-R388, result-
ing in reduction of insulin secretion. These data point to the
importance of the pancreatic IR as a target of FGFR4-R388
action. Further, they uncover Grb14 as an important mediator
of FGFR and IR crosstalk and downstream signaling to modulate
pancreatic endocrine function.
To explore the impact of the FGFR4-R388 allele and its asso-
ciated signaling dysregulation in vivo, we examined mice with
knockin of the FGFR4-R385 allele. In contrast to the increased
insulin production and enhanced glucose tolerance in FGFR4-
R385 mice, islet IR-deleted mice (Kulkarni et al., 1999a) and
IRS1-deficient mice show impaired glucose tolerance (Kulkarni
et al., 1999b). These differences can be accounted for, at least
in part, by the diminished pancreatic islet size noted in IRS1/
mice (Kulkarni et al., 1999b), which was not observed in our
FGFR4-R385 knockin mice. FGFR4-R385 knockin animals dis-
played normal pancreatic endocrine cell development and differ-
entiation. In particular, islet mass was not adversely affected in
animals carrying the FGFR4-R385 variant allele. Additionally,
measures of cell proliferation and apoptosis demonstrated no
significant differences across FGFR4 genotypes. However,
pancreatic islets from FGFR4-R385 KI mice revealed induction
of Grb14 with diminished FRS2 and IRS1 activation, consistent
with altered FGFR and IR signaling, respectively. Additionally,
primary islets derived from FGFR4-R385 KI mice showed
increased insulin secretion when examined ex vivo. Moreover,
the impact on insulin secretion was ameliorated by loss of
Grb14, highlighting the importance of FGFR4 and Grb14 in
modulating differentiated islet function.
Grb14 displays a restricted binding profile compared with the
related Grb family members, Grb7 and Grb10 (Han et al., 2001).
All Grb7/10/14 family members bind the activated kinase domain
of the IR as pseudosubstrates. Grb7 and Grb10 associate with
the IR via their BPS and SH2 domains (He et al., 1998; Kasus-
Jacobi et al., 1998), whereas at least one report suggested that
Grb14 binds mainly through its BPS domain (Kasus-Jacobi
et al., 2000). Grb14 may be more potent than Grb10 at directly
inhibiting the catalytic activity of the IR (Be´re´ziat et al., 2002).
While Grb14 has been implicated in peripheral insulin resistance,
we provide here evidence that FGFR4-R388-mediated Grb14
induction can impair IR and FGFR signaling at the level of
pancreatic insulin-producing cells. Grb14 overexpression in-
hibits FGFR actions, including fibroblast proliferation (Reilly
et al., 2000), as well as IR actions, such as insulin-stimulated
glycogen synthesis, mitogenesis, and IRS-1 phosphorylation
(Kasus-Jacobi et al., 1998). Consistent with the ability of Grb14
deficiency to restore insulin levels in FGFR4-R385 KI mice,
Grb14-null mice have been previously shown to display
improved insulin signaling and glucose tolerance (Cooney
et al., 2004). Nevertheless, several receptor tyrosine kinases
(RTKs) have also been shown to interact with Grb14 but lessell Metabolism 17, 929–940, June 4, 2013 ª2013 Elsevier Inc. 935
Figure 6. FGFR4-R385 KI Mice Display Enhanced Insulin Secretion and Glucose Tolerance
(A) To determine the in vivo impact of FGFR4 isoforms on insulin secretion 12-month-old FGFR4 knockin mice of the indicated genotypes were compared
following glucose tolerance testing on regular diet at 12 months (n = 12–15 mice/group).
(B) Glucose area under the curve (AUC) reveal tendency toward improved glucose tolerance.
(C) FGFR4-R385 KI mice display increased insulin secretion.
(D) Corresponding insulin areas under the curve AUC.
(E) Animals fed a high-fat diet (n = 15–18 mice/group) show hyperglycemia that is less evident in mice carrying an FGFR4-R385 allele.
(legend continued on next page)
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Figure 7. Loss of the Grb14 Adaptor Reverses the Effect of FGFR4-R385 on Insulin Secretion
(A and B) To determine the involvement of Grb14 in mediating FGFR4-R388 action, we generated double-mutant FGFR4-R385+//Grb14/ mice (n = 12–15
mice/group; A). Six-month-oldmice reveal that loss ofGrb14 reverses the enhanced insulin secretion by FGFR4-R385KImice. Corresponding insulin areas under
the curve are shown in (B).
(C) To exclude extrapancreatic factors inmediating insulin hypersecretion, primary islets were isolated for assessment of insulin secretion ex vivo each in triplicate
wells from FGFR4 knockin mice (n = 6–7mice/group) in the absence (0) or presence (8mmol/liter) of glucose, respectively. Pancreatic islets from FGFR4-R385+/
mice show significantly increased insulin secretion compared with those from their FGFR4-G385 littermates. FGFR4-R385+//Grb14/ islets secrete less insulin
than those from FGFR4-R385+/ animals.
Values represent mean + SEM of insulin secreted over 1 hr expressed per islet. Group comparisons were evaluated by ANOVA with levels of significance as
indicated. See also Tables S2 and S3.
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mouse studies have since unmasked tissue-specific effects for
this adaptor protein including heart (Lin et al., 2010) and retina
(Basavarajappa et al., 2011). Thus, we cannot exclude the
involvement of other RTKs and their signaling components in
mediating FGFR4-R388 actions in pancreatic islet function.
The emerging repertoire of Grb14 actions likely predicts a
distinct phenotype from those observed strictly with IR-deficient
pancreatic islet models.
Relatively little is known about how Grb14 is regulated. Here,
we show that preferential signaling by FGFR4-R388 through
STAT3/5 targets transcriptional induction of Grb14. Interestingly,
loss of Grb14 also influenced STAT3 levels, suggesting an inter-
regulatory loop between this STAT and the Grb adaptor. Given
the prominent effector functions of STAT3 in mediating onco-(F) Animals fed a high fat diet as in (E) were treated with FGF19, resulting in imp
FGFR4-R385 allele.
(G and H) Corresponding glucose AUC are shown in (G) and insulin levels in (H).
Values represent mean + SEM where group comparisons were performed by AN
Figure S4.
Cgenic signals (Yu et al., 2009), our data predict that other STAT
targets may emerge as important mediators underlying the
molecular basis of cancer-associated hyperinsulinemia.
The putative functions of FGFRs in endocrine homeostasis
have emerged principally from mouse genetic models. In partic-
ular, mice with genetic attenuation of the FGFR1c isoform
develop diabetes mellitus with age and exhibit decreased B
cell islet mass (Hart et al., 2000a). FGFR4-deficient mice develop
elevated bile acid pools and increased excretion of bile acids (Yu
et al., 2000; Tomlinson et al., 2002; Huang et al., 2007). Hepatic
restoration of wild-type FGFR4 in these animals failed to influ-
ence glucose tolerance (Yu et al., 2000; Tomlinson et al., 2002;
Huang et al., 2007). Nevertheless, FGF pharmacotherapy is gain-
ing momentum with earlier demonstration of FGF21 beneficial
effects on islet B cell function (Kharitonenkov et al., 2005; Wenterovement of hyperglycemia with a more protective effect in mice carrying an
OVA and significant differences indicated by *p < 0.05 and **p < 0.01. See also
ell Metabolism 17, 929–940, June 4, 2013 ª2013 Elsevier Inc. 937
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tive ligand FGF19 was shown to be equally as effective as
FGF21 in improving peripheral glucose uptake (Adams et al.,
2012). Our current data demonstrating improved glucose toler-
ance in FGFR4-R385 KI mice extend this model by highlighting
the biological importance of FGFR4 polymorphic variants in
modulating pharmacologic effects of FGF19. We speculate
that acting through a distinct pathway the FGFR4-R388 variant
allele adds to the pharmacologic actions of FGF19.
Our data in humans provide early evidence for the role of the
FGFR4-R388 allele in altering glucose levels and the risk of
type 2 diabetes, putatively via altered insulin secretion. Our
data are also interesting in light of recent genome-wide associa-
tion studies implicating the GRB14 locus in type 2 diabetes in
South Asians (Kooner et al., 2011). Additionally, common varia-
tions near GRB14 have also been associated with insulin secre-
tion at genome-wide statistical significance when adjusted for
BMI, which also modulates the magnitude of the genetic effect
(Manning et al., 2012; Morris et al., 2012). The gender differences
we noted across populations, however, raise caution in interpret-
ing these findings and suggest the possibility of a potential
contribution from parental gene imprinting in directing Grb14
actions. Moreover, the protective role of the FGFR4-R388 allele
against diabetes stands in contrast to the epidemiologic data
linking cancer and diabetes (Lawlor et al., 2004; Lann and
LeRoith, 2008). Instead, the enhancing effect on insulin secretion
suggests that the FGFR4-R388 allele represents an example of a
shared common program between cancer and insulin produc-
tion but not systemic insulin resistance.
In summary, we show that the heritable transmembrane
FGFR4-R388 polymorphic allele yields a functional receptor iso-
type with distinct signaling properties. Through its preferential
ability to sustain STAT activation, it transcriptionally induces
Grb14 in the endocrine pancreas to modulate insulin secretion.
Given the recognized impact of the FGFR4-R388 allele on cancer
(Bange et al., 2002; Thussbas et al., 2006), our findings unmask
this polymorphic receptor variant as a common candidate factor
linking pancreatic islet function with cancer risk and progression.EXPERIMENTAL PROCEDURES
Cells and Primary Mouse Islets
Pancreatic islet rat RINm5F cells were cultured in RPMI 1640, MIN6 cells were
grown in Dulbecco’s modified Eagle’s medium both supplemented with 10%
fetal calf serum. Primary pancreatic islets were isolated after intraductal colla-
genase injection. Phase-contrast light microscopy identified purified islets to
allow examination of an equal number of islets for overnight cultures in RPMI
1640 media. For measurement of insulin secretion, cells were cultured in the
absence and presence of glucose stimulation as indicated.
Plasmids
Prototypic FGFR4-G388 or the polymorphic FGFR4-R388 variant was
introduced as described (Ezzat et al., 2002; Stadler et al., 2006). Pools of three
to four clones of each transfectant were selected for further analyses. The
Grb14 vector was generously provided by R. Daly (Australia) and those encod-
ing STAT3 and STAT5 were provided by M. Minden (Ontario Cancer Institute).
All cDNAs were subjected to sequence fidelity verification.
siRNA Knockdown
Oligonucleotides complementary to target genes were synthesized by Ambion
(Table S4). Scrambled sequences of equal size were used as controls.938 Cell Metabolism 17, 929–940, June 4, 2013 ª2013 Elsevier Inc.Pharmacologic Treatments
FGF stimulation was performed with the non-FGFR-isotype-selective FGF-1
(Sigma, 10 ng/ml), the FGFR2-selective FGF7 (10 ng/ml, Sigma), or the
FGFR4-selective FGF19 (10 ng/ml; R&D Systems) in serum-free definedmedia
containing 10 U/ml heparin. For phosphatase inhibition, cells were serum
deprived overnight and subsequently treated with pervanadate (0.1 mM) for
15 min. For proteasomal inhibition, cells were serum deprived overnight and
subsequently treated with Calpain inhibitor I (LLnL; 50 mM) for the indicated
times. For probing of ATP-sensitive K+ channel activity, cells were treated
with diazoxide or tolbutamide (Sigma) for 20 min. followed by glucose expo-
sure for 30 min.
RNA Extraction and RT-PCR Analysis
RNA was isolated using TRIzol reagents. Primers and probes are listed in
Table S4.
Western Blotting
A complete list of primary antibodies and reaction conditions is shown in
Table S5.
Oligonucleotide Microarray Analysis
RNA extraction and array hybridization with Affymetrix U133Plus2 GeneChip
was conducted at The Centre of Applied Genomics (Hospital for Sick Children,
Toronto, Canada). Data analysis and results are shown in Table S1.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation assays were performed in accordance
with the manufacturer’s recommendations (UBI) and as previously described
(Ezzat et al., 2003). Experiments were performed on three independent
occasions and quantified by scanning densitometry (Quantity One Software;
BIO-RAD).
FGFR4 Knockin and Grb14 Knockout mice
FGFR4-R385 knockin mice were generated using standard approaches as
described previously (Seitzer et al., 2010). Grb14-deficient mice were gener-
ously provided by R. Daly and colleagues as previously described (Cooney
et al., 2004). Mouse genotyping was performed by PCR and Southern blotting.
Animals were maintained on regular or high-fat (60%) diet for 6 weeks prior to
sacrificing as indicated. Mice were also examined without and with FGF19
(Creative Biomart) administration for 7 days. The care of animals was approved
by the Institutional Animal Care facilities at the Ontario Cancer Institute
(Toronto).
Glucose Tolerance, Insulin Tolerance, and Energy Homeostasis
Testing
Fasting blood glucose from tail veins was measured after an overnight fast
with a glucose meter. Insulin wasmeasured by an ultrasensitive ELISA (Crystal
Chem) and glucagon by the Quantikine ELISA (R&D). For glucose tolerance,
20% D-glucose was injected into the peritoneal cavity at a dose of 1.5 g/kg
for 2 hr testing. For insulin tolerance testing, insulin (0.5–1 U/kg) was injected
into the peritoneal cavity. For tissue phosphorylation studies, animals were
sacrificed within 7 min after insulin administration. To measure energy
homeostasis, animals were monitored for various parameters of energy
expenditure over a 24 hr period in an indirect calorimeter chamber (Columbus
Instruments). At least six to 12 mice were included in each experiment as
indicated.
Statistical analyses
Data are shown as mean + SEM with comparisons with t tests. Multiple group
comparisons were performed by ANOVA with a statistical threshold of 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and five tables and can be found with this article online at
http://dx.doi.org/10.1016/j.cmet.2013.05.002.
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